Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified a unique circulating microRNA signature associated with severe alopecia areata, distinguishing it from other inflammatory skin conditions and suggesting these miRNAs as non-invasive biomarkers for diagnosis and potential therapeutic targets.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This review describes the toxicities associated with calcineurin inhibitors, used in kidney transplantation, which include nephrotoxicity, cardiovascular and endocrine issues, and quality of life impacts, without reporting new clinical results.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

This review highlights the significant negative impact of alopecia areata on quality of life, mental health, and work, calling for individualized approaches and effective treatments to mitigate these effects.

In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

This study found that blocking LFA-1 signaling completely prevented the development of alopecia areata in C3H/HeJ mice, suggesting that LFA-1 plays a crucial role in the disease's pathogenesis and could be a target for new therapies.

This study demonstrated that individuals with alopecia areata in Japan experience significant stigma and mental health issues, with perceived stigma and dissatisfaction with hair growth negatively correlated with disease severity.

This report from the seventh AA Research Summit discusses research highlights and sets future priorities for managing alopecia areata.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

This review discusses the unmet needs and barriers in managing alopecia areata in Latin America, highlighting access constraints and recommending coordinated efforts to improve patient outcomes with promising new treatments.

This source evaluates the clinical effectiveness of 308 nm monochromatic excimer phototherapy in treating moderate-to-severe alopecia areata, noting that both laser and lamp methods show promise without significant risks.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

This review summarizes the pathophysiology and immune mechanisms of inflammatory skin diseases like psoriasis and atopic dermatitis, highlighting the therapeutic potential of targeted immunotherapies, but reports no new clinical results.

This study found that ischemia-modified albumin (IMA) may be a promising biomarker of oxidative stress in patients with alopecia areata, offering better potential compared to other oxidative stress markers.

This study found significant structural and compositional differences in hair affected by alopecia areata compared to healthy hair, using a range of physico-chemical investigation methods.

This study in Al-Taif, KSA, observed a higher-than-expected prevalence of alopecia areata, predominantly linked to autoimmune causes, with topical corticosteroids and systemic vitamins identified as the most effective treatment.

This review discusses the role of the complement pathway in alopecia areata and reports no new clinical results; the authors suggest that targeting this pathway could offer treatment options.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

This study found that laboratory testing practices for alopecia areata vary among international hair experts, with the majority routinely conducting thyroid function and complete blood count tests, yet exhibiting diverse approaches toward testing for other conditions or before prescribing systemic therapy.

This review highlights the critical importance of a balanced diet, with adequate proteins, vitamins, and minerals, to support skin health and potentially treat inflammatory skin conditions like psoriasis and atopic dermatitis, emphasizing the need for evidence-based dietary guidance.

In this study, both alopecia areata and androgenetic alopecia were found to moderately impact quality of life, affecting emotional and social aspects in patients.

This study found that both alopecia areata and androgenetic alopecia moderately impacted patients' quality of life, affecting not only physiological but also emotional and social aspects.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.